Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6537) 6537
Publication (759) 759
Newspaper Article (348) 348
Book Review (191) 191
Newsletter (49) 49
Magazine Article (33) 33
Book Chapter (16) 16
Trade Publication Article (13) 13
Book / eBook (12) 12
Conference Proceeding (10) 10
Transcript (8) 8
Dissertation (7) 7
Reference (4) 4
Data Set (2) 2
Report (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5296) 5296
index medicus (3987) 3987
oncology (2881) 2881
imatinib mesylate (2522) 2522
male (2261) 2261
female (2228) 2228
middle aged (1773) 1773
benzamides (1706) 1706
cancer (1645) 1645
adult (1597) 1597
pyrimidines - administration & dosage (1506) 1506
hematology (1494) 1494
antineoplastic agents - administration & dosage (1482) 1482
imatinib (1462) 1462
aged (1426) 1426
piperazines - administration & dosage (1304) 1304
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (1298) 1298
treatment outcome (1288) 1288
animals (1285) 1285
research (1195) 1195
antineoplastic agents - therapeutic use (1171) 1171
dose-response relationship, drug (1096) 1096
care and treatment (1073) 1073
chronic myelogenous leukemia (1067) 1067
chemotherapy (1037) 1037
dosage and administration (1007) 1007
drug dosages (1004) 1004
chronic myeloid leukemia (987) 987
leukemia (976) 976
drug therapy (964) 964
chronic myeloid-leukemia (962) 962
pyrimidines - therapeutic use (953) 953
pharmacology & pharmacy (922) 922
piperazines - therapeutic use (824) 824
protein kinase inhibitors - administration & dosage (768) 768
tumors (750) 750
therapy (733) 733
antineoplastic combined chemotherapy protocols - therapeutic use (715) 715
antineoplastic agents (712) 712
protein kinase inhibitors - therapeutic use (707) 707
antineoplastic agents - adverse effects (673) 673
mice (673) 673
antimitotic agents (658) 658
health aspects (658) 658
mutation (657) 657
cell line, tumor (653) 653
dasatinib (653) 653
tyrosine kinase inhibitor (616) 616
antineoplastic agents - pharmacology (613) 613
apoptosis (581) 581
kinases (581) 581
cancer therapies (578) 578
pyrimidines - adverse effects (554) 554
aged, 80 and over (548) 548
pyrimidines - pharmacology (536) 536
patients (529) 529
bcr-abl (522) 522
adolescent (520) 520
clinical trials (519) 519
analysis (498) 498
protein-tyrosine kinases - antagonists & inhibitors (489) 489
hemic and lymphatic diseases (477) 477
tyrosine (474) 474
neoplasms - drug therapy (471) 471
prognosis (454) 454
young adult (450) 450
leukemia, myelogenous, chronic, bcr-abl positive - genetics (446) 446
drug resistance, neoplasm (439) 439
piperazines - adverse effects (439) 439
piperazines - pharmacology (439) 439
medicine & public health (436) 436
cell proliferation - drug effects (434) 434
protein kinase inhibitors - pharmacology (434) 434
medicine (433) 433
apoptosis - drug effects (427) 427
proteins (427) 427
disease-free survival (420) 420
risk factors (416) 416
resistance (413) 413
metastasis (411) 411
genetic aspects (410) 410
tyrosine kinase (410) 410
gastrointestinal stromal tumors - drug therapy (408) 408
leukemia, myelogenous, chronic, bcr-abl positive - pathology (405) 405
mesylate (399) 399
time factors (386) 386
fusion proteins, bcr-abl - genetics (382) 382
studies (381) 381
article (379) 379
diagnosis (379) 379
tyrosine kinase inhibitors (376) 376
drug administration schedule (373) 373
nilotinib (370) 370
complications and side effects (369) 369
expression (368) 368
research article (368) 368
protein kinase inhibitors - adverse effects (359) 359
pharmacokinetics (351) 351
in-vitro (341) 341
survival (334) 334
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6894) 6894
German (36) 36
French (29) 29
Russian (18) 18
Spanish (8) 8
Hungarian (6) 6
Polish (6) 6
Chinese (3) 3
Danish (3) 3
Dutch (3) 3
Turkish (3) 3
Italian (2) 2
Japanese (2) 2
Portuguese (2) 2
Swedish (2) 2
Czech (1) 1
Korean (1) 1
Norwegian (1) 1
Slovenian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: Two-year follow-up of a randomized phase 2 study (START-R)
by Kantarjian, Hagop and Pasquini, Ricardo and Lévy, Vincent and Jootar, Saengsuree and Holowiecki, Jerzy and Hamerschlak, Nelson and Hughes, Timothy and Bleickardt, Eric and Dejardin, David and Cortes, Jorge and Shah, Neil P
Cancer, ISSN 0008-543X, 09/2009, Volume 115, Issue 18, pp. 4136 - 4147
BACKGROUND: In patients with chronic-phase chronic myeloid leukemia (CP-CML), imatinib resistance is of increasing importance. Imatinib dose escalation was the... 
Dasatinib | Imatinib | Chronic myeloid leukemia | Drug resistance | CHRONIC MYELOGENOUS LEUKEMIA | CYTOGENETIC RESPONSES | imatinib | CYTARABINE | TYROSINE KINASE INHIBITORS | MESYLATE | INTERFERON | dasatinib | THERAPY | ONCOLOGY | chronic myeloid leukemia | drug resistance | CONFIDENCE | CML PATIENTS | ESCALATION | Piperazines - administration & dosage | Drug Administration Schedule | Follow-Up Studies | Pyrimidines - administration & dosage | Humans | Leukemia, Myeloid, Chronic-Phase - drug therapy | Middle Aged | Drug Resistance, Neoplasm | Thiazoles - therapeutic use | Withholding Treatment | Imatinib Mesylate | Piperazines - adverse effects | Thiazoles - adverse effects | Cross-Over Studies | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged, 80 and over | Adult | Female | Aged | Benzamides | Dosage and administration | Research | Drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
by Mahon, François-Xavier, Prof and Réa, Delphine, MD and Guilhot, Joëlle, PhD and Guilhot, François, Prof and Huguet, Françoise, MD and Nicolini, Franck, MD and Legros, Laurence, MD and Charbonnier, Aude, MD and Guerci, Agnès, MD and Varet, Bruno, Prof and Etienne, Gabriel, MD and Reiffers, Josy, Prof and Rousselot, Philippe, Prof and FILMC and Intergroupe Français des Leucémies Myéloïdes Chroniques
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 11, pp. 1029 - 1035
Summary Background Imatinib treatment significantly improves survival in patients with chronic myeloid leukaemia (CML), but little is known about whether... 
Hematology, Oncology and Palliative Medicine | CHRONIC MYELOGENOUS LEUKEMIA | RESPONSES | INTERFERON-ALPHA | MESYLATE DISCONTINUATION | THERAPY | CML | ONCOLOGY | COMPLETE CYTOGENETIC REMISSION | FOLLOW-UP | CYTARABINE | STEM-CELL TRANSPLANTATION | Piperazines - administration & dosage | Recurrence | Prospective Studies | Proto-Oncogene Proteins c-abl - antagonists & inhibitors | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Antineoplastic Agents - administration & dosage | Time Factors | Aged, 80 and over | Adult | Female | France | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Proto-Oncogene Proteins c-abl - genetics | Drug Administration Schedule | Pyrimidines - administration & dosage | Kaplan-Meier Estimate | Survival Rate | Treatment Outcome | Gene Expression Regulation, Leukemic | Reverse Transcriptase Polymerase Chain Reaction | Imatinib Mesylate | Remission Induction | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Fusion Proteins, bcr-abl - antagonists & inhibitors | Aged | Benzamides | Antimitotic agents | Arson | Antineoplastic agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: A phase I-II study by the Spanish group for research on sarcomas
by Maurel, Joan and Martins, Ana Sofia and Poveda, Andrés and López-Guerrero, José Antonio and Cubedo, Ricardo and Casado, Antonio and Martínez-Trufero, Javier and Ayuso, Juan Ramón and Lopez-Pousa, Antonio and Garcia-Albeniz, Xabier and Del Muro, Xavier Garcia and De Alava, Enrique
Cancer, ISSN 0008-543X, 08/2010, Volume 116, Issue 15, pp. 3692 - 3701
BACKGROUND: In KIT-expressing Ewing sarcoma cell lines, the addition of doxorubicin to imatinib increases apoptosis, compared with imatinib or doxorubicin... 
Imatinib | Wild type KIT | Gastrointestinal sarcoma tumor | Doxorubicin | PROGNOSTIC-FACTORS | RECEPTOR PATHWAY | imatinib | EWING TUMOR | MECHANISMS | CANCER | wild type KIT | MESYLATE | POSITRON-EMISSION-TOMOGRAPHY | ONCOLOGY | KIT MUTATIONS | RESISTANCE | doxorubicin | EUROPEAN-ORGANIZATION | gastrointestinal sarcoma tumor | Piperazines - administration & dosage | Drug Administration Schedule | Pyrimidines - administration & dosage | Humans | Middle Aged | Gastrointestinal Stromal Tumors - diagnostic imaging | Drug Resistance, Neoplasm | Male | Positron-Emission Tomography | Imatinib Mesylate | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Gastrointestinal Stromal Tumors - drug therapy | Aged, 80 and over | Adult | Female | Proto-Oncogene Proteins c-kit - genetics | Aged | Benzamides | Gastrointestinal Stromal Tumors - genetics | Doxorubicin - administration & dosage | Care and treatment | Sarcoma | Gastrointestinal tumors | Patient outcomes | Dosage and administration | Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: Efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily
by Saglio, Giuseppe and Hochhaus, Andreas and Goh, Yeow Tee and Masszi, Tamas and Pasquini, Ricardo and Maloisel, Frederic and Erben, Philipp and Cortes, Jorge and Paquette, Ronald and Bradley-Garelik, M. Brigid and Zhu, Chao and Dombret, Herve
Cancer, ISSN 0008-543X, 08/2010, Volume 116, Issue 16, pp. 3852 - 3861
BACKGROUND: In a phase 3 study, the authors assessed the effects of dasatinib at doses of 140 mg once daily and 70 mg twice daily in patients who had either... 
Dasatinib | Imatinib | Blast crisis | Chronic myeloid leukemia | Drug resistance | CHRONIC MYELOGENOUS LEUKEMIA | CYTOGENETIC RESPONSES | ACCELERATED PHASE | BMS-354825 | imatinib | ST1571 THERAPY | KINASE INHIBITOR | blast crisis | dasatinib | ONCOLOGY | chronic myeloid leukemia | CRISIS | drug resistance | Drug Administration Schedule | Follow-Up Studies | Pyrimidines - administration & dosage | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Drug Resistance, Neoplasm | Thiazoles - administration & dosage | Protein Kinase Inhibitors - adverse effects | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Thiazoles - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Adolescent | Pyrimidines - adverse effects | Aged, 80 and over | Adult | Aged | Benzamides | Blast Crisis | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Care and treatment | Patient outcomes | Dosage and administration | Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Imatinib and beyond—the new CML study IV
: A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia
by Berger, U and Engelich, G and Reiter, A and Hochhaus, A and Hehlmann, R and German CML Study Grp and German CML Study Group
Annals of Hematology, ISSN 0939-5555, 4/2004, Volume 83, Issue 4, pp. 258 - 264
Medicine | Stem cell transplantation | Clinical trial | Imatinib | Chronic myeloid leukemia | Interferon alpha | clinical trial | CHRONIC MYELOGENOUS LEUKEMIA | SURVIVAL | stem cell transplantation | imatinib | RESIDUAL DISEASE | FOLLOW-UP | ANTILEUKEMIC AGENTS | ABL-POSITIVE CELLS | COMPLETE CYTOGENETIC REMISSION | chronic myeloid leukemia | TYROSINE KINASE INHIBITOR | interferon alpha | MESYLATE GLEEVEC | HEMATOLOGY | MARROW TRANSPLANTS | Piperazines - administration & dosage | Prospective Studies | Pyrimidines - administration & dosage | Humans | Leukemia, Myeloid, Chronic-Phase - drug therapy | Male | Survival Rate | Piperazines - therapeutic use | Imatinib Mesylate | Cytarabine - administration & dosage | Interferon-alpha - administration & dosage | Leukemia, Myeloid, Chronic-Phase - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - therapeutic use | Female | Benzamides
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China A CHEERS-compliant article
by Wu, B and Liu, MB and Li, T and Lin, HW and Zhong, H
MEDICINE, ISSN 0025-7974, 07/2017, Volume 96, Issue 29, p. e7445
Background: The aim of the study was to test the cost-effectiveness of dasatinib compared to high-dose imatinib and nilotinib in Chinese patients who were... 
CHRONIC MYELOGENOUS LEUKEMIA | COST-EFFECTIVENESS ANALYSIS | cost-effectiveness | CML | GUIDELINES | FOLLOW-UP | Markov model | FAILURE | TYROSINE KINASE INHIBITORS | MEDICINE, GENERAL & INTERNAL | dasatinib | THERAPY | RANDOMIZED PHASE-2 | chronic myeloid leukemia | POINTS | Quality-Adjusted Life Years | Markov Chains | Protein Kinase Inhibitors - economics | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - economics | Pyrimidines - administration & dosage | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Dasatinib - economics | Drug Resistance, Neoplasm | Treatment Outcome | Antineoplastic Agents - administration & dosage | Models, Economic | Pyrimidines - economics | Antineoplastic Agents - economics | Disease Progression | Imatinib Mesylate - economics | Protein Kinase Inhibitors - administration & dosage | Health Care Costs | Dasatinib - administration & dosage | China | Cost-Benefit Analysis | Imatinib Mesylate - administration & dosage | Chronic Disease | Nilotinib | Nonlymphoid leukemia | Dosage and administration | Diagnosis | Myelocytic leukemia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor: A Randomized Trial
by Joensuu, Heikki and Eriksson, Mikael and Sundby Hall, Kirsten and Hartmann, Jörg T and Pink, Daniel and Schütte, Jochen and Ramadori, Giuliano and Hohenberger, Peter and Duyster, Justus and Al-Batran, Salah-Eddin and Schlemmer, Marcus and Bauer, Sebastian and Wardelmann, Eva and Sarlomo-Rikala, Maarit and Nilsson, Bengt and Sihto, Harri and Monge, Odd R and Bono, Petri and Kallio, Raija and Vehtari, Aki and Leinonen, Mika and Alvegård, Thor and Reichardt, Peter and Cancerepidemiologi and Onkologi och Patologi, MV and Lund University and Oncology and Pathology, MV and Cancer Epidemiology and Lunds universitet
JAMA, ISSN 0098-7484, 03/2012, Volume 307, Issue 12, pp. 1265 - 1272
CONTEXT Adjuvant imatinib administered for 12 months after surgery has improved recurrence-free survival (RFS) of patients with operable gastrointestinal... 
MESYLATE | CRITERIA | MEDICINE, GENERAL & INTERNAL | KIT MUTATIONS | RESECTION | DOSE IMATINIB | RISK | RECURRENCE | PROGNOSTICATION | STRATIFICATION | Piperazines - administration & dosage | Gastrointestinal Neoplasms - genetics | Gastrointestinal Neoplasms - drug therapy | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Young Adult | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Proto-Oncogene Proteins c-kit - genetics | Chemotherapy, Adjuvant | Gastrointestinal Stromal Tumors - genetics | Gastrointestinal Stromal Tumors - surgery | Drug Administration Schedule | Neoplasm Recurrence, Local - prevention & control | Pyrimidines - administration & dosage | Gastrointestinal Neoplasms - surgery | Treatment Outcome | Imatinib Mesylate | Piperazines - adverse effects | Gastrointestinal Stromal Tumors - drug therapy | Receptor, Platelet-Derived Growth Factor alpha - genetics | Pyrimidines - adverse effects | Survival Analysis | Aged | Benzamides | Clinical trials | Postoperative period | Drug therapy | Digestive system | Tumors | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial
by Kang, Yoon-Koo, Prof and Ryu, Min-Hee, MD and Yoo, Changhoon, MD and Ryoo, Baek-Yeol, Prof and Kim, Hyun Jin, MD and Lee, Jong Jin, MD and Nam, Byung-Ho, PhD and Ramaiya, Nikhil, MBBS and Jagannathan, Jyothi, MD and Demetri, George D, Prof
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 12, pp. 1175 - 1182
Summary Background Few treatment options remain for patients with metastatic or unresectable gastrointestinal stromal tumours (GIST) after objective... 
Hematology, Oncology and Palliative Medicine | MESYLATE | SOLID TUMORS | EFFICACY | ONCOLOGY | SAFETY | KIT | MUTATIONS | GUIDELINE | Gastrointestinal Stromal Tumors - enzymology | Piperazines - administration & dosage | Prospective Studies | Gastrointestinal Stromal Tumors - secondary | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Indoles - administration & dosage | Benzamides - administration & dosage | Time Factors | Antineoplastic Agents - adverse effects | Pyrroles - administration & dosage | Pyrroles - adverse effects | Female | Gastrointestinal Stromal Tumors - mortality | Benzamides - adverse effects | Republic of Korea | Double-Blind Method | Drug Administration Schedule | Pyrimidines - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Imatinib Mesylate | Piperazines - adverse effects | Disease Progression | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Indoles - adverse effects | Gastrointestinal Stromal Tumors - drug therapy | Pyrimidines - adverse effects | Aged | Antimitotic agents | Clinical trials | Product development | Metastasis | Antineoplastic agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: Results of the randomized IMPRES study
by Hoeper, Marius M and Barst, Robyn J and Bourge, Robert C and Feldman, Jeremy and Frost, Adaani E and Galié, Nazzareno and Gómez-Sánchez, Miguel Angel and Grimminger, Friedrich and Grünig, Ekkehard and Hassoun, Paul M and Morrell, Nicholas W and Peacock, Andrew J and Satoh, Toru and Simonneau, Gérald and Tapson, Victor F and Torres, Fernando and Lawrence, David and Quinn, Deborah A and Ghofrani, Hossein-Ardeschir
Circulation, ISSN 0009-7322, 03/2013, Volume 127, Issue 10, pp. 1128 - 1138
Background-By its inhibitory effect on platelet-derived growth factor signaling, imatinib could be efficacious in treating patients with pulmonary arterial... 
exercise | pulmonary | drugs | hypertension | hemodynamics | SURVIVAL | TRIAL | CARDIAC & CARDIOVASCULAR SYSTEMS | 6-MINUTE WALK TEST | GUIDELINES | hypertension, pulmonary | PERIPHERAL VASCULAR DISEASE | GROWTH-FACTOR EXPRESSION | BOSENTAN | Piperazines - administration & dosage | Hematoma, Subdural - physiopathology | Humans | Middle Aged | Hypertension, Pulmonary - physiopathology | Male | Protein Kinase Inhibitors - adverse effects | Exercise Tolerance - drug effects | Hematoma, Subdural - enzymology | Young Adult | Adult | Female | Hypertension, Pulmonary - drug therapy | Hypertension, Pulmonary - enzymology | Hematoma, Subdural - chemically induced | Double-Blind Method | Pyrimidines - administration & dosage | Familial Primary Pulmonary Hypertension | Imatinib Mesylate | Piperazines - adverse effects | Protein Kinase Inhibitors - administration & dosage | Exercise Tolerance - physiology | Adolescent | Pyrimidines - adverse effects | Aged | Benzamides | Usage | Drug therapy | Health aspects | Pulmonary hypertension
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial
by DeMatteo, Ronald P and Ballman, Karla V and Antonescu, Cristina R and Corless, Christopher and Kolesnikova, Violetta and Von Mehren, Margaret and McCarter, Martin D and Norton, Jeffrey and Maki, Robert G and Pisters, Peter W.T and Demetri, George D and Brennan, Murray F and Owzar, Kouros and ACOSOG and American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team for the Alliance for Clinical Trials in Oncology
Annals of Surgery, ISSN 0003-4932, 09/2013, Volume 258, Issue 3, pp. 422 - 428
Objective: To conduct the first adjuvant trial of imatinib mesylate for treatment of gastrointestinal stromal tumor (GIST). Background: GIST is the most common... 
Surgery | Imatinib mesylate | Gastrointestinal stromal tumor | SURVIVAL | MANAGEMENT | PROGNOSTIC-FACTORS | RANDOMIZED-TRIAL | PATTERNS | imatinib mesylate | LEIOMYOSARCOMAS | gastrointestinal stromal tumor | KIT | DOSE IMATINIB | RECURRENCE | MUTATIONS | surgery | Follow-Up Studies | Gastrointestinal Neoplasms - drug therapy | Gastrointestinal Neoplasms - mortality | Humans | Middle Aged | Male | Risk | Antineoplastic Agents - therapeutic use | Young Adult | Benzamides - therapeutic use | Adult | Female | Chemotherapy, Adjuvant | Gastrointestinal Stromal Tumors - mortality | Gastrointestinal Stromal Tumors - surgery | Drug Administration Schedule | Neoplasm Recurrence, Local - prevention & control | Gastrointestinal Neoplasms - surgery | Treatment Outcome | Piperazines - therapeutic use | Imatinib Mesylate | Gastrointestinal Stromal Tumors - drug therapy | Pyrimidines - therapeutic use | Adolescent | Survival Analysis | Aged
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Expanding Nilotinib Access in Clinical Trials (ENACT): An open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase
by Nicolini, Franck E and Turkina, Anna and Shen, Zhi-Xiang and Gallagher, Neil and Jootar, Saengsuree and Powell, Bayard L and De Souza, Carmino and Zheng, Ming and Szczudlo, Tomasz and Le Coutre, Philipp
Cancer, ISSN 0008-543X, 01/2012, Volume 118, Issue 1, pp. 118 - 126
Nilotinib is a selective, potent BCR-ABL inhibitor. Previous studies demonstrated the efficacy and safety of nilotinib in Philadelphia chromosome-positive... 
chronic myeloid leukemia | chronic phase | ENACT | nilotinib | BCR-ABL | Administration, Oral | Compassionate Use Trials | Pyrimidines - administration & dosage | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Drug Resistance, Neoplasm | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Pyrimidines - therapeutic use | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Aged, 80 and over | Adult | Female | Aged | Benzamides | Protein-Tyrosine Kinases - antagonists & inhibitors | Nilotinib | Care and treatment | BCR-ABL tyrosine kinase inhibitors | Chronic myeloid leukemia | Health aspects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single‐agent therapy with imatinib
by Cortes, Jorge and Jabbour, Elias and Daley, George Q and O'Brien, Susan and Verstovsek, Srdan and Ferrajoli, Alessandra and Koller, Charles and Zhu, Yali and Statkevich, Paul and Kantarjian, Hagop
Cancer, ISSN 0008-543X, 09/2007, Volume 110, Issue 6, pp. 1295 - 1302
BACKGROUND. Lonafarnib is an orally bioavailable nonpetidomimetic farnesyl transferase inhibitor with significant activity against BCR-ABL-positive cell lines... 
imatinib | chronic myeloid leukemia | phase 1 study | farnesyl transferase inhibitor | lonafarnib | Farnesyl transferase inhibitor | Imatinib | Phase 1 study | Chronic myeloid leukemia | Lonafarnib | CHRONIC MYELOGENOUS LEUKEMIA | MOLECULAR RESPONSES | KINASE INHIBITOR | DASATINIB BMS-354825 | PROTEIN TRANSFERASE | INTERFERON-ALPHA | IN-VITRO | ONCOLOGY | CHROMOSOME-POSITIVE LEUKEMIAS | CLINICAL ACTIVITY | Piperazines - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Pyridines - pharmacokinetics | Male | Fatigue - chemically induced | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Pyridines - adverse effects | Treatment Failure | Adult | Female | Piperidines - pharmacokinetics | Piperazines - pharmacokinetics | Piperidines - administration & dosage | Pyridines - administration & dosage | Drug Administration Schedule | Pyrimidines - administration & dosage | Treatment Outcome | Imatinib Mesylate | Piperazines - adverse effects | Vomiting - chemically induced | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Piperidines - adverse effects | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Aged | Benzamides | Complications and side effects | Chemotherapy, Combination | Patient outcomes | Genetic aspects | Dosage and administration | Research | Drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias
by Talpaz, Moshe and Shah, Neil P and Kantarjian, Hagop and Donato, Nicholas and Nicoll, John and Paquette, Ron and Cortes, Jorge and O'Brien, Susan and Nicaise, Claude and Bleickardt, Eric and Blackwood-Chirchir, M. Anne and Iyer, Vishwanath and Chen, Tai-Tsang and Huang, Fei and Decillis, Arthur P and Sawyers, Charles L
The New England Journal of Medicine, ISSN 0028-4793, 06/2006, Volume 354, Issue 24, pp. 2531 - 2541
Mutations in the kinase-binding domain of the BCR-ABL gene cause resistance to the BCR-ABL tyrosine kinase inhibitor imatinib in chronic myelogenous leukemia.... 
CHRONIC MYELOGENOUS LEUKEMIA | CYTOGENETIC RESPONSES | MEDICINE, GENERAL & INTERNAL | SRC/ABL KINASE INHIBITOR | IN-VITRO | CHRONIC-PHASE | TYROSINE KINASE | BCR-ABL | ACQUIRED-RESISTANCE | GENE MUTATION | CHRONIC MYELOID-LEUKEMIA | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Thiazoles - administration & dosage | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Thiazoles - adverse effects | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Antineoplastic Agents - adverse effects | Adult | Female | Neutropenia - chemically induced | Dasatinib | Piperazines | Pyrimidines - administration & dosage | Genotype | Imatinib Mesylate | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Fusion Proteins, bcr-abl - genetics | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Aged | Benzamides | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Drugs | Product/Service Evaluations | Chronic myeloid leukemia | Drug therapy | Bone marrow | Kinases | Leukemia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Influence of breast cancer resistance protein (Abcg2) and p‐glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec®) across the mouse blood–brain barrier
by Bihorel, Sébastien and Camenisch, Gian and Lemaire, Michel and Scherrmann, Jean‐Michel
Journal of Neurochemistry, ISSN 0022-3042, 09/2007, Volume 102, Issue 6, pp. 1749 - 1757
Imatinib, a protein tyrosine kinase inhibitor, may prevent the growth of glioblastoma cells. Unfortunately, its brain distribution is restricted by... 
CGP74588 | mouse | p‐glycoprotein | imatinib | blood–brain barrier | breast cancer resistance protein | Imatinib | Blood-brain barrier | Mouse | Breast cancer resistance protein | p-glycoproteinz | blood-brain barrier | CELLS | BIOCHEMISTRY & MOLECULAR BIOLOGY | p-glycoprotein | C-KIT | DRUG-RESISTANCE | DEFICIENT MICE | GF120918 | NEUROSCIENCES | REVERSAL | IN-VITRO | PHARMACOKINETICS | TYROSINE KINASE INHIBITOR | MULTIDRUG-RESISTANCE | Male | Piperazines - metabolism | Cyclosporins - pharmacology | Pyrimidines - metabolism | Quinolines - pharmacology | Antineoplastic Agents - metabolism | Brain - metabolism | Dose-Response Relationship, Drug | Brain - blood supply | ATP Binding Cassette Transporter, Subfamily B, Member 1 | ATP-Binding Cassette Transporters - genetics | Biological Transport, Active - physiology | ATP-Binding Cassette Transporters - metabolism | Dibenzocycloheptenes - pharmacology | ATP Binding Cassette Transporter, Subfamily B - genetics | Piperazines - pharmacokinetics | Immunosuppressive Agents - pharmacology | ATP Binding Cassette Transporter, Subfamily G, Member 2 | Tetrahydroisoquinolines - pharmacology | Biological Transport, Active - drug effects | Enzyme Inhibitors - pharmacology | Blood-Brain Barrier - drug effects | Imatinib Mesylate | ATP Binding Cassette Transporter, Subfamily B - metabolism | Blood-Brain Barrier - metabolism | Mice, Knockout | Brain - drug effects | Animals | ATP Binding Cassette Transporter, Subfamily B - antagonists & inhibitors | Acridines - pharmacology | Pyrimidines - pharmacokinetics | Mice | Benzamides | ATP-Binding Cassette Transporters - antagonists & inhibitors | Physiological aspects | Breast cancer | Proteins | Neurosciences | Inhibitor drugs | Rodents | Biochemistry | Glycoproteins
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights